Jalon Therapeutics develops therapeutic technology that disrupts protein-protein interactions to inactivate critical tumor signaling pathways, targeting previously untapped areas in cancer treatment. By leveraging non-oncogene addiction, the company aims to identify new therapeutic targets and create effective anticancer strategies, addressing the limitations of existing therapies.
Funding
$464.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often face limitations due to the development of resistance and the inability to target critical tumor signaling pathways effectively. Many existing treatments focus on oncogenes, leaving other potential therapeutic targets unexplored, which can lead to incomplete responses and disease recurrence.
Solution
Jalon Therapeutics is developing therapeutic technologies designed to disrupt protein-protein interactions (PPIs) within cancer cells, thereby inactivating vital tumor signaling pathways that have been previously untargeted. By focusing on non-oncogene addiction (NOA), Jalon aims to identify novel therapeutic targets that cancer cells rely on for survival, independent of oncogenes. Their lead candidate, JRT39, has been selected based on optimized sequence, superior preclinical efficacy, and favorable stability and pharmacokinetic profiles. This approach seeks to overcome the limitations of current anticancer therapies by creating more effective and safer treatment strategies. Jalon's pipeline includes JRT39, which is in advanced preclinical stages, along with six other discovery-stage candidates.
Target Audience
Jalon Therapeutics primarily targets cancer patients and healthcare providers seeking innovative and more effective anticancer therapies that address the limitations of current treatment options.
Features
- Disrupts protein-protein interactions (PPIs) to inactivate critical tumor signaling pathways.
- Focuses on non-oncogene addiction (NOA) to identify novel therapeutic targets.
- JRT39: Lead candidate with optimized sequence, superior preclinical efficacy, and favorable stability & PK profiles.
- Extensive portfolio of drug candidates in various stages of development.